Innate Pharma (IPHA) said Thursday that Sanofi (SNY) has agreed to subscribe to about 8.3 million shares of Innate at a price of 1.7974 euros ($2.05) per share for a capital increase of about 15 million euros.
The investment will be used for general corporate purposes, including extending the biotech firm's cash runway, said Innate Chief Executive Jonathan Dickinson.
The deal is expected to close on Friday, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.